&lt;p&gt;Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience&lt;/p&gt;

Xiao, Yue; Ma, Cong; Zhang, Zishu; Lee, Jun

doi:10.2147/cmar.s193948

Cited by 16 publications

(17 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these were not head-to-head comparisons, it could still be concluded that combination therapy of DEB-TACE and apatinib provided a relative and clinically meaningful improvement in OS and PFS over DEB-TACE alone or apatinib monotherapy. In the present study, we found that the median OS was longer than that of DEB-TACE monotherapy as reported by Xiao YD et al (22.0 months vs 11.5 months) (19). A slight advantage of survival time can be seen in our study when compared to that of Zhen L's study (13 months) (7).…”

Section: Discussionsupporting

confidence: 73%

“…In the current study, the liver function of patients deteriorated at first week after therapy and recovered at 1 month after the procedure. Compared to previous studies that focused on conventional TACE, the liver damage in our study was relatively less severe (18,19). Although this combination therapy achieved promising efficacy in the treatment of HCC, it is also illustrated some adverse reactions.…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma

Liu

Zhang

et al. 2020

Academic Radiology

View full text Add to dashboard Cite

Rationale and Objective: The goal of this study was to determine the clinical efficacy and safety of drug-eluting bead (DEB) transarterial chemoembolization (TACE) in combination with apatinib administration in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: From December 2015 to May 2017, a total of 32 patients with advanced HCC treated with DEB-TACE combined with apatinib were consecutively enrolled in this study. The treatment response and laboratory outcomes were assessed at the firstand third month after DEB-TACE therapy. Overall survival, progression-free survival, and adverse events were also analyzed and assessed. Results: The objective response rate and disease control rate were 62.5% and 96.9% at the first month after treatment, respectively. At the third month after the first therapy, a slightly higher objective response rate (68.8%) and lower disease control rate (90.6%) were achieved. There were no differences in the levels of aspartate aminotransferase, alanine aminotransferase, serum albumin, or total bilirubin at M1 or M3 compared to M0 (all p> 0.05) The median progression-free survival was 9.5 months (95% confidence interval, 8.1À10.9 months), and the median overall survival was 22.0 months (95% confidence interval, 20.2À23.9 months). Among the 32 patients, 2 had hypertension and 1 had grade 3 diarrhea; the rest of the patients had mild to moderate adverse reactions that were acceptable, and no serious adverse reactions occurred. Conclusion: DEB-TACE combined with apatinib is a safe and promising treatment approach for patients with advanced HCC.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 51%

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma

Liu

Zhang

et al. 2020

Academic Radiology

View full text Add to dashboard Cite

show abstract

“…In the present meta-analysis, we initially searched formally published studies to comprehensively compare the efficacy and safety of CSM-TACE with that of cTACE for treating HCC patients. A total of 16 studies and 1,454 patients with HCC were included, of whom 722 were treated with CSM-TACE and 732 were treated with cTACE (14)(15)(16)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31). CR, ORR, DCR, PFS, OS, adverse events and liver function indexes were compared and analyzed.…”

Section: Discussionmentioning

confidence: 99%

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

BackgroundDrug-eluting embolic transarterial chemoembolization (DEE-TACE) is an advance in TACE technique. However, at present there is insufficient evidence to support that DEE-TACE is superior to conventional TACE (cTACE) for hepatocellular carcinoma (HCC). The aim of this meta-analysis is to evaluate the efficacy and safety of TACE with CalliSpheres® microspheres (CSM-TACE) compared with cTACE in patients with HCC.Data SourcesPubMed, Embase, Web of Science, CNKI and Wanfang Databases were searched to identify relevant articles published before March 26, 2020. The data regarding treatment response, survival profile, adverse events and liver function indexes were retrieved.ResultsA total of 16 studies with 1454 HCC patients (722 treated with CSM-TACE and 732 with cTACE) were included. Patients receiving CSM-TACE had higher 1-month complete response (CR), objective response rate (ORR), disease control rate (DCR) (odds ratio (OR): 2.00, 95% confidence interval (95% CI): 1.29–3.09; OR: 2.87, 95% CI: 2.15–3.83; OR: 2.01, 95% CI: 1.37–2.95, respectively), 3-month CR, ORR, DCR (OR: 4.04, 95%CI: 2.46–6.64; OR: 3.39, 95%CI: 2.45–4.70; OR: 1.71, 95%CI: 1.14–2.55 respectively), and 6-month CR, ORR, DCR (OR: 4.02, 95%CI: 2.26–7.16; OR: 3.00, 95%CI: 2.05–4.38; OR: 2.66, 95%CI: 1.70–4.16 respectively) than those treated with cTACE. Furthermore, CSM-TACE exhibited a trend toward improved progression free survival (hazard ratio (HR): 0.86, 95%CI: 0.67–1.11) and overall survival (HR: 0.79, 95%CI: 0.59–1.07) over cTACE although these differences did not reach statistical significance. In terms of safety, the two TACE treatments showed similar post-treatment pain (OR: 0.84, 95%CI: 0.55–1.28), fever (OR: 0.99, 95%CI: 0.60–1.63), nausea/vomiting (OR: 0.84, 95% CI: 0.60–1.17), as well as 1-month follow-up alanine aminotransferase (Mean difference (MD): −3.66, 95%CI: −10.38–3.07), aspartate aminotransferase (MD: −2.30, 95%CI: −8.91–4.31) and total bilirubin (MD: −0.15, 95%CI: −2.26–1.96).ConclusionCSM-TACE displays superior treatment response, non-inferior survival profile and safety over cTACE in HCC patients.

show abstract

“…This is presumably because of the presence of a hepatic APS in iHCC, which intra-arterial lipiodol will pass through into the portal vein, resulting in poor deposition in the tumor area [23]. Because DEB has the property of sustained tumor-selective drug delivery and permanent embolization of tumor-feeding vessels, we believe that DEB is more appropriate than lipiodol for patients with iHCC and APS [24–26].…”

Section: Discussionmentioning

confidence: 99%

Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety

Zhang

et al. 2019

BMC Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundTo compare the efficacy and safety between conventional transarterial chemoembolization (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with infiltrative hepatocellular carcinoma (iHCC).MethodsA total of 89 iHCC patients who were treated with either cTACE (n = 33) or DEB-TACE (n = 56) between April 2013 and September 2017 were included in this retrospective study. Patients with the situations that might have a poor outcome were defined as advanced disease including Child-Pugh class B, bilobar lesions, tumor size greater than 10 cm, ECOG 1–2, tumor burden of 50–70%, and the presence of ascites, arterioportal shunt (APS), and portal venous tumor thrombus (PVTT). The tumor response was measured 1-month and 3-month after the procedure. Progression-free survival (PFS) was calculated. Toxicity was graded by Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0). The differences in tumor response, PFS, and toxicity were compared between the DEB-TACE group and cTACE group.ResultsAt 1-month and 3-month after the procedure, the objective response rate (ORR) in the overall study population was similar in DEB-TACE group and cTACE group. The disease control rate (DCR), at 1-month after the procedure, was significantly higher in the patients treated with DEB-TACE relative to those treated with cTACE (P = 0.034), while after 3 months, the difference did not differ between two groups. DEB-TACE showed a higher DCR than cTACE in patients with tumor size greater than 10 cm (P = 0.036) or associated with APS (P = 0.030) at 1-month after the procedure, while after 3 months, the difference was only noted in patients with APS (P = 0.036). The median PFS in DEB-TACE group was 96 days, while in cTACE group was 94 days, and there was no difference in PFS between two groups (P = 0.831). In the side effect analysis, abdominal pain (P = 0.034) and fever (P = 0.009) were more frequently present in the cTACE group than DEB-TACE group, but there was no difference in high grade liver toxicity between the two groups.ConclusionsCompared to cTACE, DEB-TACE offers slightly better DCR and tolerability for iHCC patients, particularly in patients associated with APS and large tumor size. However, DEB-TACE does not provide higher PFS than cTACE.

show abstract

<p>Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience</p>

Cited by 16 publications

References 26 publications

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis

Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety

Contact Info

Product

Resources

About